Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Kura Oncology has received a consensus rating of "Moderate Buy" from 14 analysts, with three rating it as a hold, ten as buy, and one as strong buy.
• The stock's average 1-year price target is $24.10, despite recent downgrades from some brokerages, including a decrease in price target by Barclays from $32 to $11.
• For the most recent quarter, Kura Oncology reported an EPS of ( $0.75 ), significantly missing the consensus estimate of $0.15, with a revenue of $15.29 million compared to the expected $64.95 million.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $24.10.

Several brokerages recently commented on KURA. Wall Street Zen lowered shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Saturday. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Barclays cut their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. JMP Securities cut their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a report on Monday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th.

Kura Oncology Stock Performance

KURA opened at $5.54 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The firm has a fifty day moving average price of $6.19 and a 200 day moving average price of $6.66. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $21.57. The stock has a market cap of $480.87 million, a P/E ratio of -2.45 and a beta of 0.41.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. Equities research analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. BVF Inc. IL boosted its stake in Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock worth $51,177,000 after buying an additional 5,186,660 shares during the period. RA Capital Management L.P. purchased a new position in Kura Oncology during the fourth quarter worth about $38,769,000. Millennium Management LLC boosted its stake in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after buying an additional 1,521,954 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Kura Oncology during the fourth quarter worth about $8,518,000. Finally, Marshall Wace LLP purchased a new position in Kura Oncology during the fourth quarter worth about $8,265,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.